Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma
Background: Over the past four decades, outcomes for osteosarcoma patients have plateaued as there have been few emerging therapies showing clinical results. Thus, the identification of novel biomarkers and therapeutic strategies are urgently needed to address these primary obstacles in patient care...
Main Authors: | Wenlong Feng, Dylan C. Dean, Francis J. Hornicek, Dimitrios Spentzos, Robert M. Hoffman, Huirong Shi, Zhenfeng Duan |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-05-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920922055 |
Similar Items
-
Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
by: Hangzhan Ma, et al.
Published: (2021-02-01) -
ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer
by: Wenlong Feng, et al.
Published: (2020-12-01) -
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcomaResearch in context
by: Hangzhan Ma, et al.
Published: (2019-01-01) -
The role of extracelluar matrix in osteosarcoma progression and metastasis
by: Juncheng Cui, et al.
Published: (2020-09-01) -
sCLU as prognostic biomarker and therapeutic target in osteosarcoma
by: Jinfeng Ma, et al.
Published: (2019-01-01)